ÜBER MICH
Dr.med. Dr.med.univ. Peter Kölblinger, MBA
Geboren und aufgewachsen in Wels, OÖ
Matura mit ausgezeichnetem Erfolg am Brucknergymnasium Wels
Studium
der Humanmedizin (Abschluss Dr.med.univ) an der Medizinischen Universität Wien
fünfmonatiger Studienaufenthalt an der University of Bristol, UK
dreimonatiger Studien- und Forschungsaufenthalt an der Wake Forest University, North Carolina, USA
Facharztausbildung
an der Universitätsklinik für Dermatologie der Salzburger Landeskliniken
einjähriger Forschungsaufenthalt - Schwerpunkt: schwarzer Hautkrebs (Melanom) – am Universitätsspital Zürich, Schweiz
Facharztdiplom Dermatologie und Venerologie
offizielle Leitung der Einheit für Dermatoonkologie (Hautkrebs) an den Salzburger Landeskliniken
Ernennung zum Oberarzt an der UK für Dermatologie und Allergologie, Salzburger Landeskliniken
Promotion
an der Universität Zürich (Abschluss Dr.med.), Dissertationsthema: „Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterize the tumour microenvironment of ulcerated primary melanomas.”
berufsbegleitendes MBA Studium (Healthcare Management) an der Wirtschaftsuniversität Wien
Ernennung zum leitenden Oberarzt für Dermatoonkologie an der UK für Dermatologie und Allergologie, Salzburger Landeskliniken
Habilitation zum Privatdozenten in Dermatologie der Paracelsus Medizinischen Privatuniversität Salzburg; Habilitationskolloquium: „Moderne Melanomtherapie: prognostische Marker, unbekannte Primärtumore und gesundheitsökonomische Betrachtungen“
Auszug wissenschaftlicher Veröffentlichungen in internationalen Fachjournalen:
Koelblinger P, Hoellwerth M, Dernoscheg MT, Koch L, Richtig E, Wanner M, Nguyen VA, Ostermann H, Bauer JW, Laimer M. Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations. J Dtsch Dermatol Ges. 2021, accepted for publication (DOI: 10.1111/ddg.14511).
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. J Immunother Cancer. 2021 Feb;9(2):e001701. PMID: 33608376.
Weber DD, Thapa M, Aminzadeh-Gohari S, Redtenbacher AS, Catalano L, Feichtinger RG, Koelblinger P, Dallmann G, Emberger M, Kofler B, Lang R. Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts. Cancers (Basel). 2021 Jan 23;13(3):434. PMID: 33498757.
Ludwig SV, F Cheng P, Mangana J, Braun R, Dummer R, Koelblinger P. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. Eur J Dermatol. 2020 Dec 1;30(6):699-709. PMID: 33459260.
Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med. 2020 Dec; 26(12):1865-1877. PMID: 33077955.
Harrer A, Lang R, Kölblinger P. Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab. Br J Dermatol. 2020 Aug;183(2):404. Epub 2020 Jul 13. PMID: 32319671.
Lazaridou MF, Gonschorek E, Massa C, Friedrich M, Handke D, Mueller A, Jasinski-Bergner S, Dummer R, Koelblinger P, Seliger B. Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. Oncoimmunology. 2020 Jun 3;9(1):1774323. PMID: 32923135.
Lazaridou MF, Massa C, Handke D, Mueller A, Friedrich M, Subbarayan K, Tretbar S, Dummer R, Koelblinger P, Seliger B. Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. J Clin Med. 2020 Aug 20;9(9):2690. PMID: 32825219
Koelblinger P, Nguyen VA, Hoeller C, Richtig E. Einfluss der Covid-19-Pandemie auf die dermatoonkologische Versorgung in Österreich. J Dtsch Dermatol Ges. 2020 Jul;18(7):778-779. PMID: 32713147.
Kaufmann C, Kempf W, Mangana J, Cheng P, Emberger M, Lang R, Kaiser AK, Lattmann E, Levesque M, Dummer R, Koelblinger P. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. Histopathology. 2020 Sep;77(3):460-470. PMID: 32374893
Fänder J, Kielstein H, Büttner M, Koelblinger P, Dummer R, Bauer M, Handke D, Wickenhauser C, Seliger B, Jasinski-Bergner S. Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget. 2019 Nov 5;10(60):6509-6525. PMID: 31741714.
Medek K, Koelblinger P, Koller J, Diem A, Ude-Schoder K, Bauer JW, Laimer M. Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab. J Dtsch Dermatol Ges. 2019 Apr;17(4):448-450. PMID: 30958923.
Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res. 2019 Jul;32(4):553-563. PMID: 30767428.
Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther. 2018 Nov 23;11: 8327-8340. PMID: 30568456.
Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):686-692. PMID: 30468696.
Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):667-675. PMID: 30357969.
Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133. PMID: 29356698.
Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J Clin Invest. 2018 Dec 3;128(12):5531-5548. PMID: 30395538.
Tsiogka A, Jansky GL, Bauer JW, Koelblinger P. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017 Oct;27(5):524-525. PMID: 28858175.
Koelblinger P, Dummer R. Targeted treatment of advanced NRAS-mutated melanoma. Oncotarget. 2017 Sep 29;8(49):84616-84617. PMID: 29156659.
Ramelyte E, Koelblinger P, Dummer R. Oestrogen receptor expression in melanoma. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1399-1400. PMID: 28815749,
Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 2017 Aug 10;6(8):e1335843. PMID: 28919996.
Koelblinger P, Dornbierer J, Dummer R. A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncol. 2017 Aug;13(20):1755-1766. PMID: 28587477.
Koelblinger P, Dummer R, Laimer M, Hecht S, Bauer JW, Gaggl A, Kugler A. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. J Eur Acad Dermatol Venereol. 2017 Jun 24. PMID: 28646606.
Kugler A, Koelblinger P, Zelger B, Ahlgrimm-Siess V, Laimer M. Papillary intralymphatic angioendothelioma (PILA), also referred to as Dabska tumour, in an 83-year-old woman. J Eur Acad Dermatol Venereol. 2015 Aug 31. PMID: 26333144.
Kölblinger P, Lang R, Hintner H, Laimer M. Bullous skin changes in a 5-month-old infant. J Dtsch Dermatol Ges. 2014 Jul;12(7):632-6. PMID: 24846296.
Koelblinger P, Dabade TS, Gustafson CJ, Davis SA, Yentzer BA, Kiracofe EA, Feldman SR. Skin manifestations of outpatient adverse drug events in the United States: a national analysis. J Cutan Med Surg. 2013 Jul- Aug; 17(4):269-75. PMID: 23815960.